BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schmidt J, Rotter M, Weiser T, Wittmann S, Weizel L, Kaiser A, Heering J, Goebel T, Angioni C, Wurglics M, Paulke A, Geisslinger G, Kahnt A, Steinhilber D, Proschak E, Merk D. A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis. J Med Chem 2017;60:7703-24. [DOI: 10.1021/acs.jmedchem.7b00398] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 8.6] [Reference Citation Analysis]
Number Citing Articles
1 Rodríguez-Soacha DA, Scheiner M, Decker M. Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands. Eur J Med Chem 2019;180:690-706. [PMID: 31401465 DOI: 10.1016/j.ejmech.2019.07.040] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
2 Imig JD. Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics. Pharmacol Ther 2018;192:1-19. [PMID: 29964123 DOI: 10.1016/j.pharmthera.2018.06.015] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
3 Luo G, Lin X, Li Z, Xiao M, Li X, Zhang D, Xiang H. Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator. Eur J Med Chem 2021;209:112910. [PMID: 33049605 DOI: 10.1016/j.ejmech.2020.112910] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Heitel P, Faudone G, Helmstädter M, Schmidt J, Kaiser A, Tjaden A, Schröder M, Müller S, Schierle S, Pollinger J, Merk D. A triple farnesoid X receptor and peroxisome proliferator-activated receptor α/δ activator reverses hepatic fibrosis in diet-induced NASH in mice. Commun Chem 2020;3. [DOI: 10.1038/s42004-020-00411-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Friedrich L, Cingolani G, Ko YH, Iaselli M, Miciaccia M, Perrone MG, Neukirch K, Bobinger V, Merk D, Hofstetter RK, Werz O, Koeberle A, Scilimati A, Schneider G. Learning from Nature: From a Marine Natural Product to Synthetic Cyclooxygenase-1 Inhibitors by Automated De Novo Design. Adv Sci (Weinh) 2021;8:e2100832. [PMID: 34176236 DOI: 10.1002/advs.202100832] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
6 Bachon A, Steinkamp A, Bolm C. N-Arylated Sulfoximines as Cross-Coupling Building Blocks. Adv Synth Catal 2018;360:1088-93. [DOI: 10.1002/adsc.201701394] [Cited by in Crossref: 9] [Article Influence: 2.3] [Reference Citation Analysis]
7 Boeckmans J, Natale A, Buyl K, Rogiers V, De Kock J, Vanhaecke T, Rodrigues RM. Human-based systems: Mechanistic NASH modelling just around the corner? Pharmacol Res 2018;134:257-67. [PMID: 29964161 DOI: 10.1016/j.phrs.2018.06.029] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
8 Gabler M, Kramer J, Schmidt J, Pollinger J, Weber J, Kaiser A, Löhr F, Proschak E, Schubert-Zsilavecz M, Merk D. Allosteric modulation of the farnesoid X receptor by a small molecule. Sci Rep 2018;8:6846. [PMID: 29717168 DOI: 10.1038/s41598-018-25158-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
9 Wu R, Liu S, Liu Y, Sun Y, Xiao H, Huang Y, Yang Z, Wu Z. PET probe with Aggregation Induced Emission characteristics for the specific turn-on of aromatase. Talanta 2020;208:120412. [DOI: 10.1016/j.talanta.2019.120412] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Iyer MR, Kundu B, Wood CM. Soluble epoxide hydrolase inhibitors: an overview and patent review from the last decade. Expert Opin Ther Pat 2022;:1-19. [PMID: 35410559 DOI: 10.1080/13543776.2022.2054329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Das Mahapatra A, Choubey R, Datta B. Small Molecule Soluble Epoxide Hydrolase Inhibitors in Multitarget and Combination Therapies for Inflammation and Cancer. Molecules 2020;25:E5488. [PMID: 33255197 DOI: 10.3390/molecules25235488] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Dai L, Feng Z, Zha R, Cheng K, Wen X, Sun H, Yuan H. Discovery of Novel Peroxisome Proliferator-Activated Receptor α (PPARα) Agonists by Virtual Screening and Biological Evaluation. J Chem Inf Model 2020;60:1717-27. [DOI: 10.1021/acs.jcim.9b00838] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Zhang L, Li H, Pan W, Khan FU, Qian C, Qi-li F, Xu X. Novel hepatoprotective role of Leonurine hydrochloride against experimental non-alcoholic steatohepatitis mediated via AMPK/SREBP1 signaling pathway. Biomedicine & Pharmacotherapy 2019;110:571-81. [DOI: 10.1016/j.biopha.2018.12.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
14 Shu X, Li M, Cao Y, Li C, Zhou W, Ji G, Zhang L. Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation. Front Pharmacol 2021;12:750826. [PMID: 34603061 DOI: 10.3389/fphar.2021.750826] [Reference Citation Analysis]
15 Merk D, Grisoni F, Schaller K, Friedrich L, Schneider G. Discovery of Novel Molecular Frameworks of Farnesoid X Receptor Modulators by Ensemble Machine Learning. ChemistryOpen 2019;8:7-14. [PMID: 30622878 DOI: 10.1002/open.201800156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Schierle S, Neumann S, Heitel P, Willems S, Kaiser A, Pollinger J, Merk D. Design and Structural Optimization of Dual FXR/PPARδ Activators. J Med Chem 2020;63:8369-79. [PMID: 32687365 DOI: 10.1021/acs.jmedchem.0c00618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Merk D, Grisoni F, Friedrich L, Gelzinyte E, Schneider G. Computer-Assisted Discovery of Retinoid X Receptor Modulating Natural Products and Isofunctional Mimetics. J Med Chem 2018;61:5442-7. [DOI: 10.1021/acs.jmedchem.8b00494] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
18 Schierle S, Helmstädter M, Schmidt J, Hartmann M, Horz M, Kaiser A, Weizel L, Heitel P, Proschak A, Hernandez-Olmos V, Proschak E, Merk D. Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast. ChemMedChem 2020;15:50-67. [PMID: 31670489 DOI: 10.1002/cmdc.201900576] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
19 Hye Khan MA, Schmidt J, Stavniichuk A, Imig JD, Merk D. A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice. Biochem Pharmacol 2019;166:212-21. [PMID: 31129048 DOI: 10.1016/j.bcp.2019.05.023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
20 Schierle S, Schmidt J, Kaiser A, Merk D. Selective Optimization of Pranlukast to Farnesoid X Receptor Modulators. ChemMedChem 2018;13:2530-45. [DOI: 10.1002/cmdc.201800549] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
21 Lillich FF, Imig JD, Proschak E. Multi-Target Approaches in Metabolic Syndrome. Front Pharmacol 2020;11:554961. [PMID: 33776749 DOI: 10.3389/fphar.2020.554961] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Kalveram L, Schunck WH, Rothe M, Rudolph B, Loddenkemper C, Holzhütter HG, Henning S, Bufler P, Schulz M, Meierhofer D, Zhang IW, Weylandt KH, Wiegand S, Hudert CA. Regulation of the cytochrome P450 epoxyeicosanoid pathway is associated with distinct histologic features in pediatric non-alcoholic fatty liver disease. Prostaglandins Leukot Essent Fatty Acids 2021;164:102229. [PMID: 33388475 DOI: 10.1016/j.plefa.2020.102229] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Sun CP, Zhang XY, Morisseau C, Hwang SH, Zhang ZJ, Hammock BD, Ma XC. Discovery of Soluble Epoxide Hydrolase Inhibitors from Chemical Synthesis and Natural Products. J Med Chem 2021;64:184-215. [PMID: 33369424 DOI: 10.1021/acs.jmedchem.0c01507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
24 Li X, Li X, Liu F, Li S, Shi D. Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist. J Med Chem 2021;64:10581-605. [PMID: 34313432 DOI: 10.1021/acs.jmedchem.1c00683] [Reference Citation Analysis]
25 Brunst S, Kramer JS, Kilu W, Heering J, Pollinger J, Hiesinger K, George S, Steinhilber D, Merk D, Proschak E. Systematic Assessment of Fragment Identification for Multitarget Drug Design. ChemMedChem 2021;16:1088-92. [PMID: 33283450 DOI: 10.1002/cmdc.202000858] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Waheed A, Ahmad T, Haroon M, Ullah N. A Highly Sensitive and Selective Fluorescent Sensor for Zinc(II) Ions Based on a 1,2,3‐Triazolyl‐Functionalized 2,2’‐Dipicolylamine (DPA). ChemistrySelect 2020;5:5300-5. [DOI: 10.1002/slct.202000928] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
27 Codony S, Pont C, Griñán-Ferré C, Di Pede-Mattatelli A, Calvó-Tusell C, Feixas F, Osuna S, Jarné-Ferrer J, Naldi M, Bartolini M, Loza MI, Brea J, Pérez B, Bartra C, Sanfeliu C, Juárez-Jiménez J, Morisseau C, Hammock BD, Pallàs M, Vázquez S, Muñoz-Torrero D. Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease. J Med Chem 2022. [PMID: 35271276 DOI: 10.1021/acs.jmedchem.1c02150] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
28 Heitel P, Gellrich L, Heering J, Goebel T, Kahnt A, Proschak E, Schubert-Zsilavecz M, Merk D. Urate transporter inhibitor lesinurad is a selective peroxisome proliferator-activated receptor gamma modulator (sPPARγM) in vitro. Sci Rep 2018;8:13554. [PMID: 30202096 DOI: 10.1038/s41598-018-31833-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
29 Pollinger J, Schierle S, Neumann S, Ohrndorf J, Kaiser A, Merk D. Computer-Assisted Selective Optimization of Side-Activities-from Cinalukast to a PPARα Modulator. ChemMedChem 2019;14:1343-8. [PMID: 31141287 DOI: 10.1002/cmdc.201900286] [Reference Citation Analysis]
30 Schierle S, Flauaus C, Heitel P, Willems S, Schmidt J, Kaiser A, Weizel L, Goebel T, Kahnt AS, Geisslinger G, Steinhilber D, Wurglics M, Rovati GE, Schmidtko A, Proschak E, Merk D. Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology. J Med Chem 2018;61:5758-64. [DOI: 10.1021/acs.jmedchem.8b00458] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
31 Merk D, Grisoni F, Friedrich L, Schneider G. Tuning artificial intelligence on the de novo design of natural-product-inspired retinoid X receptor modulators. Commun Chem 2018;1. [DOI: 10.1038/s42004-018-0068-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
32 Sampietro A, Pérez-areales FJ, Martínez P, Arce EM, Galdeano C, Muñoz-torrero D. Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis. Pharmaceuticals 2022;15:545. [DOI: 10.3390/ph15050545] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Proschak E, Stark H, Merk D. Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds. J Med Chem 2019;62:420-44. [PMID: 30035545 DOI: 10.1021/acs.jmedchem.8b00760] [Cited by in Crossref: 144] [Cited by in F6Publishing: 119] [Article Influence: 36.0] [Reference Citation Analysis]
34 Hao YY, Cui WW, Gao HL, Wang MY, Liu Y, Li CR, Hou YL, Jia ZH. Jinlida granules ameliorate the high-fat-diet induced liver injury in mice by antagonising hepatocytes pyroptosis. Pharm Biol 2022;60:274-81. [PMID: 35138995 DOI: 10.1080/13880209.2022.2029501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Schierle S, Brunst S, Helmstädter M, Ebert R, Kramer JS, Steinhilber D, Proschak E, Merk D. Development and in vitro Profiling of Dual FXR/LTA4H Modulators. ChemMedChem 2021;16:2366-74. [PMID: 33856122 DOI: 10.1002/cmdc.202100118] [Reference Citation Analysis]
36 Pollinger J, Gellrich L, Schierle S, Kilu W, Schmidt J, Kalinowsky L, Ohrndorf J, Kaiser A, Heering J, Proschak E, Merk D. Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation. J Med Chem 2019;62:2112-26. [PMID: 30702885 DOI: 10.1021/acs.jmedchem.8b01848] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
37 Lillich FF, Willems S, Ni X, Kilu W, Borkowsky C, Brodsky M, Kramer JS, Brunst S, Hernandez-Olmos V, Heering J, Schierle S, Kestner RI, Mayser FM, Helmstädter M, Göbel T, Weizel L, Namgaladze D, Kaiser A, Steinhilber D, Pfeilschifter W, Kahnt AS, Proschak A, Chaikuad A, Knapp S, Merk D, Proschak E. Structure-Based Design of Dual Partial Peroxisome Proliferator-Activated Receptor γ Agonists/Soluble Epoxide Hydrolase Inhibitors. J Med Chem 2021;64:17259-76. [PMID: 34818007 DOI: 10.1021/acs.jmedchem.1c01331] [Reference Citation Analysis]
38 Karmakar U, Samanta R. Pd(II)-Catalyzed Direct Sulfonylation of Benzylamines Using Sodium Sulfinates. J Org Chem 2019;84:2850-61. [DOI: 10.1021/acs.joc.8b03098] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
39 H M Ehrler J, Brunst S, Tjaden A, Kilu W, Heering J, Hernandez-Olmos V, Krommes A, Kramer JS, Steinhilber D, Schubert-Zsilavecz M, Müller-Knapp S, Merk D, Proschak E. Compilation and Evaluation of Fatty Acid Mimetics Screening Library. Biochem Pharmacol 2022;:115191. [PMID: 35907497 DOI: 10.1016/j.bcp.2022.115191] [Reference Citation Analysis]
40 Tian L, Zhang Q, Ablajan K. Iodine-Promoted N-Acylation of Amines with Hydrazide: An Efficient Metal-Free Amidation. Synthesis. [DOI: 10.1055/a-1838-9491] [Reference Citation Analysis]
41 Grisoni F, Merk D, Byrne R, Schneider G. Scaffold-Hopping from Synthetic Drugs by Holistic Molecular Representation. Sci Rep 2018;8:16469. [PMID: 30405170 DOI: 10.1038/s41598-018-34677-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
42 Luan Z, Huo X, Dong P, Tian X, Sun C, Lv X, Feng L, Ning J, Wang C, Zhang B, Ma X. Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism. European Journal of Medicinal Chemistry 2019;182:111652. [DOI: 10.1016/j.ejmech.2019.111652] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
43 Helmstädter M, Vietor J, Sommer J, Schierle S, Willems S, Kaiser A, Schmidt J, Merk D. A New FXR Ligand Chemotype with Agonist/Antagonist Switch. ACS Med Chem Lett 2021;12:267-74. [PMID: 33603974 DOI: 10.1021/acsmedchemlett.0c00647] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
44 Hiesinger K, Wagner KM, Hammock BD, Proschak E, Hwang SH. Development of multitarget agents possessing soluble epoxide hydrolase inhibitory activity. Prostaglandins Other Lipid Mediat 2019;140:31-9. [PMID: 30593866 DOI: 10.1016/j.prostaglandins.2018.12.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
45 Meijer I, Willems S, Ni X, Heering J, Chaikuad A, Merk D. Chemical Starting Matter for HNF4α Ligand Discovery and Chemogenomics. Int J Mol Sci 2020;21:E7895. [PMID: 33114319 DOI: 10.3390/ijms21217895] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Helmstädter M, Kaiser A, Brunst S, Schmidt J, Ronchetti R, Weizel L, Proschak E, Merk D. Second-Generation Dual FXR/sEH Modulators with Optimized Pharmacokinetics. J Med Chem 2021;64:9525-36. [PMID: 34165993 DOI: 10.1021/acs.jmedchem.1c00831] [Reference Citation Analysis]
47 Heering J, Merk D. Hybrid Reporter Gene Assays: Versatile In Vitro Tools to Characterize Nuclear Receptor Modulators. In: Badr MZ, editor. Nuclear Receptors. New York: Springer; 2019. pp. 175-92. [DOI: 10.1007/978-1-4939-9195-2_14] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
48 Merk D, Grisoni F, Friedrich L, Gelzinyte E, Schneider G. Scaffold hopping from synthetic RXR modulators by virtual screening and de novo design. Medchemcomm 2018;9:1289-92. [PMID: 30151082 DOI: 10.1039/c8md00134k] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
49 Merk D, Friedrich L, Grisoni F, Schneider G. De Novo Design of Bioactive Small Molecules by Artificial Intelligence. Mol Inform. 2018;37. [PMID: 29319225 DOI: 10.1002/minf.201700153] [Cited by in Crossref: 120] [Cited by in F6Publishing: 95] [Article Influence: 30.0] [Reference Citation Analysis]
50 Helmstädter M, Schmidt J, Kaiser A, Weizel L, Proschak E, Merk D. Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice. ACS Pharmacol Transl Sci 2021;4:966-79. [PMID: 33860214 DOI: 10.1021/acsptsci.1c00041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]